Total
0
Shares
Mesoblast (ASX:MSB) - Managing Director and CEO, Silviu Itescu (centre).
Managing Director and CEO, Silviu Itescu (centre).
Source: Mesoblast
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Mesoblast (MSB) has raised US$90 million (A$138 million) to manufacture its cell therapy treatment for COVID-19 patients with respiratory failure
  • Last month, the company found its treatment was 83 per cent effective against COVID-19 patients with acute respiratory distress syndrome (ARDS)
  • Mesoblast issued 43 million shares to existing and new institutional investors at a price of $3.20 per share
  • Majority of the funds will be used to scale-up manufacturing, while the remaining fund will be used for working capital and corporate purposes
  • Mesoblast is down 4.07 per cent on the market this morning, trading for $3.30 per share

Mesoblast (MSB) has raised US$90 million (A$138 million) to manufacture its cell therapy treatment, remestemcel-L treatment, for COVID-19 patients.

Last month, the company found its treatment was 83 per cent effective against COVID-19 patients with acute respiratory distress syndrome (ARDS).

The trial showed that 75 per cent of the COVID-19 patients had successfully come off ventilator support around 10 days after the treatment.

In contrast, one New York hospital network only saw a 12 per cent survival rate using the standard of care within the same period Mesoblast treated its patients.

Placement

Mesoblast issued 43 million shares to existing and new institutional investors at a price of $3.20 per share.

The majority of the funds will be used to scale-up manufacturing of remestemcel-L for the treatment of critically ill patients suffering from diseases caused by cytokine release syndromes associated with high mortality, particularly COVID-19.

The remaining funds will be used for working capital and general corporate purposes.

“We greatly appreciate the support shown by both our existing investors and new institutional investors, with demand for the placement far exceeding the funds raised,” Chief Executive Dr Silviu Itescu said.

“We look forward to updating the market as this important COVID-19 ARDS trial progresses and to its completion in the coming months,” he added.

Mesoblast is down 4.07 per cent on the market this morning, trading for $3.30 per share at 11:24 am AEST.

MSB by the numbers
More From The Market Herald
APM (ASX:APM) - CEO, Michael Anghie

" APM Human Services (ASX:APM) expands, acquiring Lifecare

APM Human Services International (APM) has acquired physiotherapy and home care group Lifecare for $68 million.
Resonance Health (ASX:RHT)

" Resonance Health (ASX:RHT) submits LiverSmart to FDA

Resonance Health (RHT) has submitted its LiverSmart device to the Food and Drug Administration (FDA) for US regulatory clearance.
Dotz Nano (ASX:DTZ) - CEO, Gideon Shmuel

" Dotz Nano (ASX:DTZ) signs Malaysian distribution deal for COVID-19 tests

Dotz Nano (DTZ) has entered into a distribution agreement with ScienceVision to promote, sell and distribute its COVID-19 virus detection technology in Malaysia.
Kazia Therapeutics (ASX:KZA) - CEO, Dr James Garner

" Kazia Therapeutics (ASX:KZA) releases “positive” second-phase study results for brain cancer treatment

Kazia Therapeutics (KZA) has opened the trading day green after reporting positive final results from a second-phase clinical study of its paxalisib drug